Lupin Limited will conduct an earnings call for the first quarter of FY27 on August 7, 2026, at 16:30 IST. The meeting is organized to discuss the company's financial performance for the quarter ended June 30, 2026, and will be accessible via Zoom following prior registration.

The announcement was made in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Amit Kumar Gupta, Company Secretary & Compliance Officer, signed the regulatory filing submitted to the National Stock Exchange of India Limited and BSE Limited.

Participants are required to register for the conference call in advance. The invitation link for the Zoom registration is enclosed with the official notice. Attendees are advised to join the session by 16:25 Hrs IST on the scheduled date to ensure a timely start.

Earnings Call Details

Lupin Limited announced the strategic spin-out of two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), through its wholly owned subsidiary Lupin Inc., into Kaveri Therapeutics Inc. This move aims to advance the programs through global clinical trials for solid tumors. Under the agreement, Lupin Inc. acquired an 82.2% equity stake in Kaveri, consisting of 332,000 Common Shares, and provided seed funding in exchange for exclusive rights to the two assets. The transaction, valued at USD 1.6 million, was completed on July 20, 2026.

Kaveri Therapeutics is a clinical-stage oncology company incorporated in Delaware, U.S.A., on May 20, 2026. The entity reported nil turnover and net worth at the time of filing. Kaveri will operate independently under the leadership of Chief Executive Officer Kristi Jones and Chief Medical Officer Dr. Robert Pierce. The company intends to raise additional capital to fund its clinical development efforts, focusing on biomarker-driven strategies for hard-to-treat cancers including lung, pancreatic, ovarian, and CNS-related malignancies.

The oncology programs involved have demonstrated encouraging clinical progress. LNP7457 (PRMT5) and LNP8701 (SOS1) reported positive data at the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively. Vinita Gupta, Chief Executive Officer of Lupin, stated that the strength of these assets, combined with Kaveri's leadership, positions the company to accelerate the development of targeted therapies.

Key Transaction Details

The disclosure was submitted to the National Stock Exchange of India and BSE Limited under Regulation 30 of the SEBI Listing Regulations. The transaction aligns with Lupin's strategy to innovate in targeted oncology therapies by spinning out specific programs to specialized entities.